Technology News and Research

RSS

PLAN C Agency launches Hepatitis B awareness campaign in the West Coast

PLAN C Agency, in collaboration with biopharmaceutical company Gilead Sciences, launched a Hepatitis B awareness campaign titled "B HERE" at three college campuses in the West Coast. The goal was to raise the much needed awareness regarding the rising epidemic of Hepatitis B among Asian Americans and educate the youth on the importance of getting tested.

11 Feb 2010

10th Annual Spring Meeting of ESC on Cardiovascular Nursing and Allied Professionals

Geneva, situated at the heart of Europe, provides a fitting setting for the 10th Annual Spring Meeting of the European Society of Cardiology Council (ESC) on Cardiovascular Nursing and Allied Professionals (CCNAP), 12 - 13 March 2010, with its special theme: "Uniting to Improve Cardiovascular Practice".

11 Feb 2010

CINJ researchers develop new vaccine strategy for pancreatic cancer

More than 42,500 people in the United States were diagnosed with pancreatic cancer last year and nearly 35,200 died from the disease, according to The American Cancer Society.

11 Feb 2010

Cambrex announces fourth-quarter financial results ended December 31, 2009

Cambrex Corporation reports fourth quarter results for the period ended December 31, 2009.

10 Feb 2010

Candela receives SFDA approval to market its laser systems throughout China

Candela Corporation, a Syneron company, announced today that the SFDA (State Food and Drug Administration) of China has approved the Alex TriVantage® multi-wavelength, Q-switched laser system and the GentleMax® multiple wavelength workstation for sale throughout the People's Republic of China, including Hong Kong.

10 Feb 2010

Boston Scientific reports fourth quarter and full year 2009 results

Boston Scientific Corporation today announced financial results for the fourth quarter and full year ended December 31, 2009, as well as guidance for net sales and earnings per share (EPS) for the first quarter and full year 2010.

10 Feb 2010

Allylix raises $6M in first closing of Series C financing

Allylix Inc. announced today that it has raised $6 million in the first closing of its Series C financing. The money will allow the Company to commercialize its first three products for the food and fragrance industry, and allow it to advance several additional products in its pipeline.

10 Feb 2010

Trimel BioPharma Holdings updates business developments

Trimel BioPharma Holdings Inc. is today providing an update on a number of operational items that have contributed significantly to advancing the Company and achieving its initial objectives.

10 Feb 2010

EMEA grants Genta's request for SME designation

Genta Incorporated announced that it has received $2.8 million in non-dilutive cash proceeds from the sale of net operating tax losses and research tax credits generated in prior tax years as part of the Technology Business Tax Certificate Program sponsored by the New Jersey Economic Development Authority (NJEDA), pursuant to the rules, regulations and stipulations set forth by the program.

10 Feb 2010

Emerging Healthcare Solutions receives honor of admission to the President’s Club of NBCC

Emerging Healthcare Solutions, Inc. announced today that it has received the honor of admission to the President’s Club of the National Black Chamber of Commerce www.nationalbcc.org. Membership in the exclusive President’s Club is an honor that establishes nationwide recognition of Emerging Healthcare Solutions in the healthcare industry and helps engineer policies and initiatives that benefit minority business development in healthcare.

10 Feb 2010

Seaside Therapeutics granted U.S patent covering methods of treating autism

Seaside Therapeutics LLC today announced the issuance of U.S. patent 7,648,993 B2 (‘993 patent), which covers methods of treating autism with group 1 antagonists of the metabotropic glutamate receptor (mGluR) pathway. An earlier related patent, U.S. patent 6,890,931 B2 (‘931 patent), was issued in 2005 and covers methods of treating Fragile X Syndrome, the most common known cause of autism, with group 1 antagonists of the mGluR pathway.

10 Feb 2010

AB SCIEX technology solution implemented for anti-doping enforcement at the 2010 Winter Games

While millions of viewers around the world are watching breathtaking ski jumps, razor-sharp skating moves and other awe-inspiring athletic feats in Vancouver over the next few weeks, the official doping control laboratory of the 2010 Winter Games will be casting an equally intent eye on the athletes who are competing.

10 Feb 2010

Getinge Canada named 'Top 50 Best Small and Medium Employers in Canada' for 2009

Getinge Canada Limited is honoured to be named among the Top 50 Best Small and Medium Employers in Canada for 2009. This reflects positively on the employees and their engagement in the growth of this organization. The study, now in its sixth year, is published in the Globe and Mail and PROFIT Magazine.

10 Feb 2010

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo.

10 Feb 2010

Practice Fusion patient survey: Doctors are making use of EHR systems

The health IT landscape has changed fundamentally in the first year since the American Recovery and Reinvestment Act was signed into law. American patients are seeing their doctors make the switch to Electronic Health Record (EHR) systems, according to a survey conducted by GfK Roper for Practice Fusion, the fastest growing EHR community in the US.

10 Feb 2010

STDUniversity.org launches interactive, personalized STD test recommendation

STDUniversity.org is the first website to provide an interactive, personalized STD test recommendation developed by academic and medical experts. This expert-based tool incorporates screening guidelines from the Centers for Disease Control and Prevention (CDC), U.S. Agency for Healthcare Research and Quality (AHRQ), and the U.S. Preventive Service Task Force (USPSTF).

10 Feb 2010

IndicatorEDG survey reveals Americans find less chance of achieving personal dreams

Luth Research's IndicatorEDG survey finds Americans are less likely to feel their dreams are attainable. Back in the third quarter of 2006, 62% of Americans said they had an excellent, very good or good chance of achieving their personal dreams.

10 Feb 2010

Alexza Pharmaceuticals announces development and commercialization collaboration with Biovail Laboratories International

Alexza Pharmaceuticals, Inc. announced today that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 (Staccato® loxapine) in the U.S. and Canada. AZ-004 is Alexza's lead program, based on the company's proprietary technology, the Staccato system. Alexza submitted its New Drug Application (NDA) for Staccato loxapine in December 2009. Alexza is seeking regulatory approval to market AZ-004, an inhalation product candidate developed for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.

10 Feb 2010

Kinexus Bioinformatics announces the commercial release of Protein Kinase Microarray

Kinexus Bioinformatics Corporation announced the commercial release of its novel Protein Kinase Microarray with 200 recombinant human protein kinases for screening. The microarray has wide utility including applications for drug target counter screening, to identify novel kinase substrates, establish kinase antibody specificities, and for the discovery and testing of protein kinase-protein and protein kinase-compound interactions.

10 Feb 2010

Second-quarter fiscal 2010 results announced by Bioniche Life Sciences

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 second quarter, ended December 31, 2009.

10 Feb 2010

Technology News and Research

PLAN C Agency launches Hepatitis B awareness campaign in the West Coast

10th Annual Spring Meeting of ESC on Cardiovascular Nursing and Allied Professionals

CINJ researchers develop new vaccine strategy for pancreatic cancer

Cambrex announces fourth-quarter financial results ended December 31, 2009

Candela receives SFDA approval to market its laser systems throughout China

Boston Scientific reports fourth quarter and full year 2009 results

Allylix raises $6M in first closing of Series C financing

Trimel BioPharma Holdings updates business developments

EMEA grants Genta's request for SME designation

Emerging Healthcare Solutions receives honor of admission to the President’s Club of NBCC

Seaside Therapeutics granted U.S patent covering methods of treating autism

AB SCIEX technology solution implemented for anti-doping enforcement at the 2010 Winter Games

Getinge Canada named 'Top 50 Best Small and Medium Employers in Canada' for 2009

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Practice Fusion patient survey: Doctors are making use of EHR systems

STDUniversity.org launches interactive, personalized STD test recommendation

IndicatorEDG survey reveals Americans find less chance of achieving personal dreams

Alexza Pharmaceuticals announces development and commercialization collaboration with Biovail Laboratories International

Kinexus Bioinformatics announces the commercial release of Protein Kinase Microarray

Second-quarter fiscal 2010 results announced by Bioniche Life Sciences

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News